Search results
Author(s):
Derek P Chew
,
Harvey D White
Added:
3 years ago
Effective translation of reperfusion therapy to mortality reductions in ST-segment elevation myocardial infarction (STEMI) remains both time-critical in its implementation and dependent on optimal antithrombotic therapy. Innumerable clinical studies have explored several antithrombin and antiplatelet therapies in the immediate management of STEMI. With the wide array of the therapies now…
View more
Author(s):
Iosif Xenogiannis
,
Charalampos Varlamos
,
Despoina-Rafailia Benetou
,
et al
Added:
2 years ago
Author(s):
Jeffrey Tabas
Added:
3 years ago
Approximately five million people present to the emergency department (ED) each year with chest pain, and billions of dollars are spent on assessment and treatment. Many therapies are time-dependent, so rapid identification of patients with acute coronary syndrome (ACS) - unstable angina (UA) and acute myocardial infarction (MI) - at high risk for adverse outcomes is essential. Missed or…
View more
The Impact of Haemorrhagic Complications on Mortality in Acute Coronary Syndromes—Implications for…
Author(s):
Steven V Manoukian
,
Michele D Voeltz
,
Frederick Feit
Added:
3 years ago
Article
Author(s):
Jeffrey Tabas
Added:
3 years ago
Approximately five million people present to the emergency department (ED) each year with chest pain, and billions of dollars are spent on assessment and treatment. Many therapies are time-dependent, so rapid identification of patients with acute coronary syndrome (ACS) - unstable angina (UA) and acute myocardial infarction (MI) - at high risk for adverse outcomes is essential. Missed or…
View more
ESC 23: The RIGHT Study
Author(s):
Yan Yan
,
Gilles Montalescot
Added:
7 months ago
Video
Author(s):
Steve Attanasio
,
Raed Al Dallow
,
Sandeep Nathan
Added:
3 years ago
While acute coronary syndromes inclusive of ST-elevation myocardial infarction (STEMI) have been described in patients with polycythemia vera (PCV), optimal pharmacologic and interventional management strategies in the setting of drastically elevated platelet counts remain unclear.1 To our knowledge this is the first reported case of STEMI with massive thrombus burden in a patient with PCV…
View more
Author(s):
Robert Barcelona
Added:
1 year ago
Author(s):
Antonio Gutierrez
,
Sunil V Rao
Added:
3 years ago
Current evidence-based therapies for ischemic heart disease include antithrombotic and antiplatelet medications that reduce the risk for ischemic outcomes such as myocardial infarction and stroke.1 Given their mechanism of action, bleeding is a risk with these agents, especially when combined with invasive procedures.2 In addition to overt bleeding, clinical trials of antithrombotic strategies…
View more
Author(s):
Sandeep Nathan
,
Rajiv Swamy
Added:
3 years ago
The spectrum of acute coronary syndromes (ACS) encompasses a broad array of clinical characteristics and risk strata, ranging from unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI) to ST-segment elevation myocardial infarction (STEMI) and sudden cardiac death (SCD). In this article, UA and NSTEMI will be considered together as non-ST-segment elevation acute coronary…
View more